nodes	percent_of_prediction	percent_of_DWPC	metapath
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0547	0.0547	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0535	0.0535	CbGpPWpGaD
Betaxolol—ADRB1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0467	0.0467	CbGpPWpGaD
Betaxolol—ADRB2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0457	0.0457	CbGpPWpGaD
Betaxolol—ADRB1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0453	0.0453	CbGpPWpGaD
Betaxolol—ADRB2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0443	0.0443	CbGpPWpGaD
Betaxolol—ADRB1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0422	0.0422	CbGpPWpGaD
Betaxolol—ADRB2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0413	0.0413	CbGpPWpGaD
Betaxolol—ADRB1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0392	0.0392	CbGpPWpGaD
Betaxolol—ADRB2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0384	0.0384	CbGpPWpGaD
Betaxolol—ADRB1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0381	0.0381	CbGpPWpGaD
Betaxolol—ADRB2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0373	0.0373	CbGpPWpGaD
Betaxolol—ADRB1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0355	0.0355	CbGpPWpGaD
Betaxolol—ADRB2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0347	0.0347	CbGpPWpGaD
Betaxolol—ADRB1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0296	0.0296	CbGpPWpGaD
Betaxolol—ADRB2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0289	0.0289	CbGpPWpGaD
Betaxolol—ADRB1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0248	0.0248	CbGpPWpGaD
Betaxolol—ADRB2—Arf6 signaling events—MET—Gilles de la Tourette syndrome	0.0246	0.0246	CbGpPWpGaD
Betaxolol—ADRB2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0243	0.0243	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.0203	0.0203	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.0197	0.0197	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.0128	0.0128	CbGpPWpGaD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00901	0.00901	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00881	0.00881	CbGpPWpGaD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00874	0.00874	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00855	0.00855	CbGpPWpGaD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00814	0.00814	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00797	0.00797	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00772	0.00772	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00755	0.00755	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00749	0.00749	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00733	0.00733	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00698	0.00698	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00683	0.00683	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00588	0.00588	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00575	0.00575	CbGpPWpGaD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.0057	0.0057	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.0057	0.0057	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00558	0.00558	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00558	0.00558	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00531	0.00531	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.0052	0.0052	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00489	0.00489	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00478	0.00478	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00372	0.00372	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00364	0.00364	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00332	0.00332	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00325	0.00325	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00322	0.00322	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00315	0.00315	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00302	0.00302	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.003	0.003	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00295	0.00295	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00294	0.00294	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00293	0.00293	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00286	0.00286	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	0.00276	0.00276	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00273	0.00273	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00267	0.00267	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—HDC—Gilles de la Tourette syndrome	0.00234	0.00234	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.0021	0.0021	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00206	0.00206	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00191	0.00191	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00187	0.00187	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00178	0.00178	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00174	0.00174	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00173	0.00173	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00169	0.00169	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00161	0.00161	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00158	0.00158	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00113	0.00113	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.0011	0.0011	CbGpPWpGaD
